Global Idiopathic Pulmonary Fibrosis Market is valued at USD 3295.6 Million in 2021 and is expected to reach USD 5326.8 Million by 2028 with a CAGR of 7.1% over the forecast period.
Global Idiopathic Pulmonary Fibrosis Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2028: Increasing geriatric population, rising smokers population, increasing prevalence of fibrotic diseases, and growing demand for idiopathic pulmonary fibrosis are some of the major factors driving the growth of the Global Idiopathic Pulmonary Fibrosis Market.
Idiopathic pulmonary fibrosis (IPF) is a chronic lung infection portrayed by a moderate and irreversible decline in lung function, in which the dividers of the air sacs (called alveoli) become thickened and harmed. Idiopathic pulmonary fibrosis (IPF) is a condition wherein the lungs become scarred and breathing turns out to be progressively difficult. Common symptoms include dry cough, shortness of breath, sticky nails, and fatigue. Other symptoms include weight loss and muscle and joint pain. Further complications include high blood pressure, heart failure, pulmonary embolism, or pneumonia. Major causes of lung damage include abdominal acid reflux, Epstein-Barr virus, and some viruses like herpes zoster or environmental factors such as silica dust, asbestos fibers, hard metal dust, and charcoal dust. Treatments for idiopathic pulmonary fibrosis (IPF) include oxygen therapy, pulmonary rehabilitation, symptom management, and lung transplantation. Prescribed antifibrotic drugs include pirfenidone and Nintedanib.
The Covid-19 pandemic has shown a negative impact on the growth of the global idiopathic pulmonary fibrosis market owing to the decrease in the number of idiopathic pulmonary fibrosis patient visits in hospitals & clinics for idiopathic pulmonary fibrosis therapy (IPF), as patients are more susceptible to Covid-19 infection. Furthermore, the outbreak of Covid-19 has led to a decline in most markets, especially idiopathic pulmonary fibrosis.
Global idiopathic pulmonary fibrosis market is segmented on the basis of the drug type, distribution channel, and region & country level. On the basis of drug type, the global idiopathic pulmonary fibrosis market is segmented into Nintedanib and pirfenidone. By distribution channel, the market is classified into hospital pharmacies, online pharmacies, and retail pharmacies.
Some major key players for the global idiopathic pulmonary fibrosis market report cover prominent players like
On May 15th, 2022; Boehringer Ingelheim released Phase II data for BI 1015550, a new test phosphodiesterase 4B (PDE4B) inhibitor, published in the New England Journal of Medicine. The 12-week promising data showing a decrease in lung function in patients with idiopathic pulmonary fibrosis (IPF) was presented at the American thoracic society (ATS) international conference breaking news session on May 16 in San Francisco.
On May 12th, 2022; Sandoz, a global leader in generic and biosimilar drugs, announced the US launch of the generic paraphenidone, idiopathic pulmonary fibrosis (IPF), the equivalent of Genetek's Esbriet. Prescription Oral Medicine is readily available to patients through a special pharmacy, with a $ 0 co-pay program for eligible patients.
On October 14th, 2020; Glenmark Pharma announced the launch in India of a generic version of NINDANIB, used to treat pulmonary fibrosis. ""In India Glenmark is a leader in the field of respiratory diseases & is the first organization to launch a reasonable branded generic version for the therapy of pulmonary fibrosis.
One of the major factors driving the growth of the idiopathic pulmonary fibrosis market is the increasing geriatric population. Idiopathic aspiratory fibrosis (IPF) is a chronic interstitial lung sickness (ILD) described by clinical side effects like dyspnea, cough, and expanding immobility. IPF happens basically in patients over 60 years old, for which reason an association with maturing processes has been thought of. The maturing lung is dependent upon natural changes which make it more vulnerable to infection. Due to this demographic change, the number and proportion of more than 60 people have increased. The geriatric population is more likely to suffer from idiopathic pulmonary fibrosis is likely to boost the market growth. For instance; according to United Nation, in 2019, there were 703 million people aged 65 in the world. The number of geriatric people is projected to double to 1.5 billion by 2050.
In addition, the rising smoker population is also boosting the growth of the idiopathic pulmonary fibrosis market. The number of cigarette smokers globally has increased because of population growth. For instance; according to World Health Organization, on July 26th, 2021; Tobacco kills more than 8 million people every year. Of these, more than 7 million deaths are due to direct tobacco use, while about 1.2 million are the result of second-hand smoke exposure to non-smokers. More than 80% of the world's 1.3 billion tobacco users live in low- and middle-income countries. Therefore, the rising smoker population has driven the global idiopathic pulmonary fibrosis market. Furthermore, the increasing prevalence of fibrotic diseases is another factor to boosts the idiopathic pulmonary fibrosis market. Fibrotic is a pathological characteristic of most chronic inflammatory infections. Fibrotic, or scarring, is defined by the accumulation of additional extracellular matrix components. If it is extremely progressive, the fibrotic process ultimately leads to organ failure and death. In various diseases such as liver cirrhosis, pulmonary fibrotic, renal interstitial fibrosis, myocardial infarction, systemic sclerosis (SSC), and graft-versus-host disease (GVHD), fibrotic remodelling can lead to impaired organ function. For instance; according to the National Library of Medicine, in January 2019; Liver disease kills approximately two million people worldwide each year, one million due to cirrhosis complications, and one million because of viral hepatitis and hepatocellular carcinoma. Liver cirrhosis is more likely to suffer from idiopathic pulmonary fibrosis.
Moreover, the growing demand for idiopathic pulmonary fibrosis is another factor to boosts the idiopathic pulmonary fibrosis market. For instance, as per the news published, on 12th May 2022; Sandoz launched the first generic pirfenidone in the US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio. Thus, increasing demand for idiopathic pulmonary fibrosis so idiopathic pulmonary fibrosis has been launched.
However, the high cost associated with idiopathic pulmonary fibrosis is hampering the growth of the global idiopathic pulmonary fibrosis market. In spite of that, increasing demand for idiopathic pulmonary fibrosis is some opportunity in the global idiopathic pulmonary fibrosis market over the forecast period.
Geographically, North America is expected to dominate the global idiopathic pulmonary fibrosis market within the forecast period due to the increasing incidences of cancer, rising geriatric population, and growing smoking habits in this region. The increasing incidences of cancer are boosting the market growth in the North American region. For instance; according to National Cancer Institute, in 2020, 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease. And, increasing geriatric population is also fostering market growth as the geriatric population is more prone to idiopathic pulmonary fibrosis. For instance; according to Rural Health Information Hub, on April 6th, 2019; there were 46 million people aged 65 in the US. The number of geriatric people is projected to double to 90 million by 2050.
The Asia Pacific is expected to show significant growth in the global idiopathic pulmonary fibrosis market due to rising demand for idiopathic pulmonary fibrosis, growing improvement in R & D facilities, and increasing developing economic conditions in this region. For instance; as per the news published, on October 14th, 2020; Glenmark Pharma launched a pulmonary fibrosis treatment drug in India.
Middle East and Africa
|2015 - 2020
|2021 - 2028
|Market Size in 2021:
|USD 3295.6 Million
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 5326.8 Million
|Tables, Charts & Figures:
|Companies / key Players
|Biogen Inc., Boehringer Ingelheim, FibroGen, Inc., GNI Group Ltd, Galapagos NV, Biogen, Bristol-Myers Squibb Company., Mission Therapeutics., F. Hoffmann-La Roche, AstraZeneca Plc, and others.
|By Drug Type, By Distribution Channel
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®